[0001] The invention relates to a method to produce a polymer by means of a radical polymerisation
process involving the use of a container containing specific organic peroxide formulations
that can be handled, produced, and shipped in a safe manner and where the organic
peroxide formulations contained therein can be used in polymerisation processes where
the resulting polymer has a reduced level of undesired residues of low-molecular weight
and/or inert phlegmatising agents.
[0002] Organic peroxides have long been known. Due to the safety hazards associated with
most of them, they are often diluted with one or more specific solvents, also known
as phlegmatisers. Classical phlegmatising agents are hydrocarbons and esters, such
as phthalates.
[0003] US 4,131,728 discloses a polymerisation process employing shock-sensitive peroxides in improved
phlegmatisers. The improved phlegmatisers are specific monomers that do not homopolymerise.
Exemplified suitable phlegmatising monomers are maleic and citraconic anhydride and
esters thereof, fumarates and fumaronitriles, cinnamates and cinnamonitriles, and
stilbene.
[0004] US 4,029,875 discloses an ethylene polymerisation process employing a mixture of organic peroxides
and cyclic olefins, styrene, or styrene homologues bearing alkyl substituents on the
benzene nucleus to reduce the consumption of initiator in the process and to improve
the optical and mechanical properties of the polyethylene produced.
[0005] Yu.A. Alexandrov et al. disclose in Journal of Organometallic Chemistry, 157 (1978),
267-274, that silicon subgroup organoelement peroxides (peroxides where one Sl, Ge or Sn
atom is attached to the peroxygen function) in model studies showed specific decomposition
behaviour and that the ratio of proton abstraction and addition to double bonds varies
depending on the olefin that is used as the solvent. The present invention does not
relate to silicon subgroup organoelement peroxides.
[0006] In
WO 96/03397, disclosing particular safe cyclic ketone formulations, a variety of potential phlegmatisers
is mentioned. However, ketone peroxides, including cyclic ketone peroxides, are not
the subject of the present invention. It is noted that Akzo Nobel markets formulations
of tert. butyl peroxymaleate in dibutylmaleate solvent for specific use in unsaturated
polyester resin curing processes with specific curing profiles.
[0007] Although many phlegmatisers are known and although reactive compounds have been combined
with certain organic peroxides before, there is a need in the industry for packaged
peroxide formulations that can be produced, handled, and shipped in a safe manner
and where the peroxide formulations, when used in polymerisation reactions, do not
lead to the presence of undesired phlegmatising agent in the resin that is produced.
The most pressing need is for the supply of peroxides for use in the styrenics and
high-pressure ethylene (co)polymerisation industry, where the phlegmatising agent
as such should not end up in the final resin. However, such improved formulations
which would reduce the amount of low-molecular weight (<1,000 Dalton) products, especially
solvents, in the final product could be beneficial also in the process of making acrylic
resins, to modify polymers, e.g. polypropylene, and to cure or cross-link polymers,
such as polyethylene and unsaturated polyester resins.
[0008] In the styrenics industry it is preferred, especially when expandable polystyrene
is produced using a suspension polymerisation process, that the phlegmatiser is a-polar
in nature to prevent the final resin from becoming more hydrophilic, which interferes
with the foaming process. Due to the nature of the polymerisation process, relatively
small quantities of concentrated, preferably technically pure, peroxide formulations
are used. Traditionally, containers shipped for use in this industry are less than
500 litres, preferably less than 250 litres, more preferably less than 30 litres in
size. For economic reasons and to reduce the amount of packaging material, the container
will preferably contain more than 1 litre, more preferably more than 2 litres, most
preferably more than 10 litres of the (phlegmatised) peroxide, such as the Nourytainers®
ex Akzo Nobel. There is a need for a "drop in" replacement for the existing products,
so that polymerisation recipes need not be changed, which leads to an improved product
(containing less low-molecular weight compounds). However, there is also a need for
more dilute peroxide formulations, which, for example, could be dosed automatically
and/or stored safely in large-size (200 litres, preferably 500 litres or more) storage
tanks.
[0009] In the high-pressure ethylene (co)polymerisation process, typically very dilute peroxide
formulations, often containing just 10-40%w/w of peroxide and 60-90%w/w of phlegmatiser,
are supplied. Particularly in these processes it is highly desirable that most if
not all of the phlegmatiser be consumed or reacted, so that the resulting polymer
contains an acceptably low amount of phlegmatiser. It is noted that because quite
dilute peroxide formulations are to be supplied, it is preferred that the safety characteristics
of the formulations are such that the container in which the peroxide formulations
are shipped is at least 200 litres, preferably at least 1,000 litres, most preferably
more than 10,000 litres in size.
[0010] Furthermore, there is a prejudice against shipping and storing large containers which
contain peroxides in combination with reactive compounds for fear of increasing the
hazards associated with the handling of said organic peroxides. More particularly,
containers containing a peroxide will show a run-away thermal decomposition, also
known as a thermal explosion, whenever the heat developing in the container due to
decomposition of the peroxide is higher than the heat transmitted to the surroundings.
The larger a (practical) container, the lower the surface to volume ratio will be.
Therefore, shipment in larger containers is more hazardous. The presence of reactive
compounds in peroxide formulations has always been expected to result in a less safe
product, because the heat of reaction will contribute to the heat being generated,
while the heat transfer to the surroundings is not increased. Hence, the shipment
of peroxides dissolved in reactive compounds has never been commercialised, except
for some peroxydicarbonates which have been shipped in monomers with allylic unsaturated
groups which do not readily polymerise and must be shipped at very low and impractical
temperature of-20°C, or in monomers that do not homopolymerise at all (meaning that
no more than 1% of the monomer is converted in a test where a 1:1 weight ratio mixture
of monomer and peroxide is kept at 40°C for a period of 100 hours).
[0011] Surprisingly, we have found that containers with a size of more than 1 litre and
containing organic peroxides and reactive diluents can nevertheless be shipped in
a safe fashion at temperatures above -20°C, preferably above-10°C, more preferably
above 0°C. The use of the reactive diluent gives the benefit of reduced unbound phlegmatiser
in the polymer (so that the polymer contains less volatile product). Particularly
in a high-pressure ethylene (co)polymerisation process, the phlegmatiser is consumed
without the properties of the polymer being changed and without the polymerisation
process being adversely affected. The reduced unbound phlegmatiser levels improve
the organoleptic properties of the resulting (co)polymer and may even obviate a vacuum
treatment of the molten polymer to reduce volatile material.
[0012] Accordingly, we claim a method to produce a polymer by means of a radical polymerisation
process according to claim 1, particularly the (co)polymerisation process of ethylene
at high pressure to make so-called (modified) low density polyethylene (LDPE) and
the suspension polymerisation process to make expandable polystyrene. However, as
said, the peroxide formulations may be equally desirable in other conventional radical
polymerisation, curing, and/or modification processes.
[0013] The flash point is determined in accordance with method ISO 3679 using a Setaflash
tester (model 1374 and a sample of 2 ml for flash points up to 110°C and/or a model
1377 and a sample of 4 ml for flash points from 110-300°C). The boiling point is determined
in accordance with EU Council Directive 92/69/EEC of July 31, 1993 (17th adaptation
of Council Directive 67/548/EEC) using a Mettler TA-4000 DSC at a temperature scanning
rate of 5°C/min using a sample cup with a lid with a pin hole of about 0.5 mm. The
experiments were carried out in duplicate. The boiling point is the average of the
onset temperatures as determined by intersecting the base line and the extrapolated
line touching most of the shoulder of the front of the endotherm peak. Preferably,
the boiling point of the reactive phlegmatiser is above 60°C. The SADT is determined
a conventional way, using a Differential Scanning Calorimeter (DSC) that is heated
at a rate of 2°C per minute. The sample size is about 60 mg, the cups that are used
of the type ME HP stainless steel, 270 µl. The SADT is defined to be the temperature
that is 50°C below the temperature where the total heat developed is 100W per kg of
sample.
[0014] Preferably, the containers are more than 200 litres, more preferably more than 1,000
litres, most preferably more than 10,000 litres in size. Preferably, they contain
80-2 %w/w of peroxide, more preferably 75-5%w/w, and most preferably 50-10%w/w of
peroxide. The higher concentrations (>40%w/w) are preferred when small containers
are used (holding less than 200 litres, preferably less than 50 litres, of product),
while the lower concentrations (<40%w/w) are preferred when the formulations are shipped
in larger containers holding 200 litres or more of the peroxide formulation.
[0015] A preferred group of peroxides for shipment in accordance with the present invention
are peroxides comprising one or more of the following moieties; peroxyester of the
formula -C(O)OO-, peroxycarbonate of the formula -OC(O)OO-, diacylperoxide of the
formula -C(O)OOC(O)-, dialkylperoxide of the formula -OO-, and trioxepan as disclosed
in European Patent Application No.
00203888.3, so that peroxides of this group include mixed peroxides (containing any two different
peroxygen-bearing moieties in one molecule), and mixtures of any two or more of these
peroxides. It is noted that If the peroxides are not liquid at room temperature, they
may be soluble in the phlegmatiser or mixture of phlegmatisers. Although the peroxides
can be oligomeric or polymeric in nature, it is preferred that they are of the conventional
type comprising one, two or three peroxygen bonds in the molecule. Most preferred
are (di)peroxyesters, such as 1,1,4,4-tetramethylbutyl-1,4-di(peroxy-2-methylpropanoate),
tert-butylperoxy neodecanoate, tert-amylperoxy neodecanoate, 1,1,3,3-tetramethyl butyl-1-peroxy
neodecanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy neodecanoate, tert-butylperoxy
pivalate, tert-amylperoxy pivalate, 1,1,3,3-tetramethyl butyl-1-peroxy pivalate, 1,1-dimethyl-3-hydroxy
butyl-1-peroxy pivalate, tert-butylperoxy 2-ethylhexanoate, tert-amylperoxy 2-ethylhexanoate,
1,1,3,3-tetramethyl butyl-1-peroxy 2-ethylhexanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy
2-ethylhexanoate, tert-butylperoxy benzoate, tert-amylperoxy benzoate, 1,1,3,3-tetramethyl
butyl-1-peroxy benzoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy benzoate, tert-butylperoxy
3,3,5-trimethylhexanoate, tert-amylperoxy 3,3,5-trimethylhexanoate, 1,1,3,3-tetramethyl
butyl-1-peroxy 3,3,5-trimethylhexanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy 3,3,5-trimethylhexanoate,
tert-butylperoxy isobutyrate, tert-amylperoxy isobutyrate, 1,1,3,3-tetramethyl butyl-1-peroxy
isobutyrate, and 1,1-dimethyl-3-hydroxy butyl-1-peroxy isobutyrate, dialkylperoxides,
such as di-tert-butyl peroxide, tert-butyl tert-amyl peroxide, and di-tert-amyl peroxide,
and diacyl peroxides, such as bis(3,3,5-trimethylhexanoyl) peroxide. Preferably, the
peroxides are not shock-sensitive.
[0016] The reactive phlegmatiser used in accordance with the present invention must react
efficiently in the polymerisation process employing the peroxide formulation. The
term "react efficiently" as used herein means that at least 25%, preferably at least
50%, and most preferably more than 75% by weight of the reactive phlegmatiser is reacted
In the polymerisation process. In other words, in the most preferred situation, less
than 25% by weight of the phlegmatiser used in the process is extractable from the
resin (without destruction of the resin). Reaction conditions vary widely; take, for
example, the differences between a suspension polymerisation process of styrene, where
the bulk of the monomer is typically reacted at temperatures of up to about 100°C
at about atmospheric pressure (1 bara), and high-pressure ethylene polymerisation
processes, which are conducted at temperatures up to 400°C and pressures up to 3,500
bara. The skilled person knows that the reactivity of the phlegmatiser used according
to the invention depends on the reaction conditions, such as temperature, pressure,
radical concentration, monomer concentration, and the type of monomer. However, whether
or not it is a reactive phlegmatiser is easily tested by checking the amount of unreacted
phlegmatiser in the polymer. It is to be understood that the term "reactive phlegmatiser"
does not relate to conventional phlegmatisers, which do not react and often plasticise
the resulting resin.
[0017] It is essential that the reactive phlegmatiser fulfil the flash and boiling point
requirements. If it does not, then it is less preferred and can it only be used together
with one or more other reactive or conventional phlegmatisers such that the mixture
does fulfil the flash and boiling point requirements.
[0018] It is furthermore to be noted that the reactive phlegmatizers do not encompass regular
monomers as used in radical homopolymerization processes, such as styrene and methylmethacrylate.
A convenient way to discriminate between suitable reactive phlegmatizers according
to the invention and undesired phlegmatizer/solvents, is to determine the SADT of
a 50/50 blend, on a weight basis, of a peroxide and a known inert phlegmatizer, such
as octane or isododecane, and the SADT of a 50/50 blend of the same peroxide and the
reactive phlegmatizer. If the SADT is lowered by 5°C or more, the phlegmatizer is
not a reactive phlegmatizer according to the invention. Preferably, the SADT is not
lowered at all, or even increased.
[0019] The reactive phlegmatiser is selected from the group consisting of 1-hexene, 1-heptene,
1-octene, 1-nonene, 1-decene, 1-undecene, and 1-dodecene, and mixtures thereof.
[0020] The formulations can be produced by blending one or more pure peroxides with one
or more of the reactive phlegmatisers. Alternatively, one or more peroxides containing
conventional diluents/phlegmatisers can be blended with one or more of the reactive
phlegmatisers. Also, it is possible to produce the peroxide in a medium comprising
one or more of the reactive phlegmatisers and, optionally, conventional phlegmatiser,
such that the packaged end product of the peroxide synthesis step, optionally after
one or more other process steps, e.g. a washing step, is a packed peroxide formulation
according to the invention. Preferably, the final formulation is essentially free
of chlorinated species, since such species may lead to corrosion problems or interfere
with the polymerisation process in which the formulations are used as a source of
free radicals.
[0021] Conventional phlegmatisers are selected from hydrocarbons, such as (diesel) fuel,
paraffinic and white oils, oxygenated hydrocarbons, such as ethers, epoxides, and
esters. Examples of preferred conventional phlegmatisers are hydrocarbon solvents,
including isododecane, toluene, xylene, (diesel) fuel, paraffinic oils, and white
oils, esters, such as phthalates and adipates, ethers, and epoxides, such as epoxidised
soybean oil.
[0022] Preferably, the peroxide formulations according to the invention comprise: 75-1 percent
by weight, based on the weight of the formulation, (%w/w) of one or more of the organic
peroxides, 25-99 %w/w of one or more reactive phlegmatisers, and 0-50 %w/w of one
or more conventional phlegmatisers selected from hydrocarbons and oxygenated hydrocarbons,
up to a total of 100 %w/w.
[0023] The polymerisation processes for which the peroxide (initiator) formulations acoording
to the invention are pre-eminently suited are of the conventional type, and include
processes to make poly vinyl chloride, copolymers of vinyl chloride, poly(meth)acrylate
(co)polymers, etc. Preferably, the process is a styrene suspension (co)polymerisation
or a high-pressure (co)polymerisation process of ethylene. Comonomers that may be
used in the (co)polymerisation process of ethylene are of the conventional type and
include alkenes, such as propene, (cyclo)hexene and (cyclo)octene, and vinyl acetate.
Comonomers that may be used in the (co)polymerisation process of styrene are of the
conventional type and include divinylbenzene. The amount of initiator used in these
conventional (co)pelymerisation processes will vary, depending on the polymerisation
temperature, the capacity for removing the heat of polymerisation, the kind(s) of
monomer(s) used, and the applied pressure. Usually, from 0.001-25%w/w of initiator,
based on the total weight of the monomers, is employed. Preferably, from 0.001-15%w/w
of initiator is employed.
[0024] A most preferred embodiment of the invention is the transport of large containers
(≥200 litres) containing 75-1%w/w, preferably 50-10%w/w, of one or more organic peroxides
selected from the group of tert-butylperoxy neodecanoate, tert-amylperoxy neodecanoate,
1,1,3,3-tetramethyl butyl-1-peroxy neodecanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy
neodecanoate, tert-butylperoxy pivalate, tert-amylperoxy pivalate, 1,1,3,3-tetramethyl
butyl-1-peroxy pivalate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy pivalate, tert-butylperoxy
2-ethylhexanoate, tert-amylperoxy 2-ethylhexanoate, 1,1,3,3-tetramethyl butyl-1-peroxy
2-ethylhexanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy 2-ethylhexanoate, tert-butylperoxy
benzoate, tert-amylperoxy benzoate, 1,1,3,3-tetramethyl butyl-1-peroxy benzoate, 1,1-dimethyl-3-hydroxy
butyl-1-peroxy benzoate, tert-butylperoxy 3,3,5-trimethylhexanoate, tert-amylperoxy
3,3,5-trimethylhexanoate, 1,1,3,3-tetramethyl butyl-1-peroxy 3,3,5-trimethylhexanoate,
1,1-dimethyl-3-hydroxy butyl-1-peroxy 3,3,5-trimethylhexanoate, tert-butylperoxy isobutyrate,
tert-amylperoxy isobutyrate, 1,1,3,3-tetramethyl butyl-1-peroxy isobutyrate, 1,1-dimethyl-3-hydroxy
butyl-1-peroxy isobutyrate, di-tert-butyl peroxide, tert-butyl tert-amyl peroxide,
di-tert-amyl peroxide, bis(3,3,5-trimethylhexanoyl) peroxide, 25-99%w/w of one or
more reactive phlegmatisers, most preferably 1-octene, and 0-50%w/w of one or more
conventional phlegmatisers, up to a total of 100%w/w.
[0025] Since the thus transportable peroxide formulations are pre-eminently suited for use
in high-pressure ethylene polymerisation processes, a further preferred embodiment
of the invention is the method to (co)polymerise ethylene in a conventional high-pressure
radical polymerisation process in which peroxides are produced at another site (i.e.
off-site), formulated with a reactive phlegmatiser, safely transported to the polymerisation
site, and used in the polymerisation process.
[0026] Another most preferred embodiment of the invention relates to the transport of containers
containing 75-1%w/w of 1,1,4,4-tetramethylbutyl-1,4-di(peroxy-2-methylpropanoate),
25-99%w/w of one or more reactive phlegmatisers, and 0-50%w/w of one or more conventional
phlegmatisers, up to a total of 100%w/w.
[0027] Since the thus transportable peroxide formulations are pre-eminently suited for use
in styrene suspension polymerisation processes, a further preferred embodiment of
the invention is the method to (co)polymerise styrene in a conventional suspension
polymerisation process in which peroxides are produced at another site (i.e. off-site),
formulated with a reactive phlegmatiser, safely transported to the polymerisation
site, and used in the polymerisation process.
[0028] The invention is elucidated by the following examples.
Example 1 and Comparative Example A
[0029] In Example 1, tert-butylperoxy 2-ethylhexanoate (Trigonox 21® ex Akzo Nobel) was
diluted with 1-octene (ex Acros organics, product 12944-0000) in a ratio of 1:1 on
a weight basis.
[0030] The experiment was repeated in Comparative Example A using n-octane (ex Haltermann
GmbH, No. F122900) instead of 1-octene.
[0031] Both formulations have about equal safety characteristics, which is expected to allow
their shipment in 1.000-litre containers. More particularly, both formulations have
a SADT of 40°C. It is noted that a similar tert-butylperoxy 2-ethylhexanoate dilution
with styrene resulted in a formulation that is outside the scope of the present invention
with a SADT of 30°C. The use of the formulation of Example 1, compared to the use
of the product of Comparative Example A, in a high-pressure (co)polymerisation process
is expected to result in a much reduced amount of volatile matter in the resulting
(modified) LDPE.
1. A method to produce a polymer by means of a radical polymerisation process wherein
at least 25%w/w of the phlegmatiser that was used to phlegmatise the peroxide or peroxides
used as a source of free radicals in said process is reacted such that it is not extractable
from the polymer by transporting a peroxide formulation-containing container to the
polymerisation unit and introducing its content into the polymerisation process, said
container having a size greater than 1 litre and being filled with:
• from 90 to 1 %w/w of one or more peroxides selected from the group consisting of
peroxyesters, including peroxyester derivatives of ketone peroxides, peroxycarbonates,
including peroxycarbonate derivatives of ketone peroxides, diacylperoxides with from
1 to 48 carbon atoms, diperoxyketals, trioxepans, dialkylperoxides, mixed peroxides
containing two different peroxygen-bearing moieties in one molecule, and mixtures
of any two or more of these peroxides,
• from 10 to 99%w/w of one or more phlegmatisers with a (joint) flash point greater
than 5°C and a (joint) boiling point that is more than 60°C higher than the self-accelerating
decomposition temperature of the peroxide formulation, said phlegmatiser being selected
from the group consisting of 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 1-undecen,
1-dodecene, and mixtures thereof,
• 0-75%w/w of optional conventional phlegmatisers selected from hydrocarbons and oxygenated
hydrocarbons,
up to a total of 100%.
2. The method according to claim 1 wherein the polymerisation process is a high-pressure
ethylene (co)polymerisation process.
3. The method according to claim 1 wherein the polymerisation process is a suspension
styrene (co)polymerisation process.
4. A method according to any one of the preceding claims wherein the peroxide is selected
from the group consisting of 1,1,4,4-tetramethylbutyl-1,4-di(peroxy-2-methylpropanoate),
tert-butylperoxy neodecanoate, tert-amylperoxy neodecanoate, 1,1,3,3-tetramethyl butyl-1-peroxy
neodecanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy neodecanoate, tert-butylperoxy
pivalate, tert-amylperoxy pivalate, 1,1,3,3-tetramethyl butyl-1-peroxy pivalate, 1,1-dimethyl-3-hydroxy
butyl-1-peroxy pivalate, tert-butylperoxy 2-ethylhexanoate, tert-amylperoxy 2-ethylhexanoate,
1,1,3,3-tetramethyl butyl-1-peroxy 2-ethylhexanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy
2-ethylhexanoate, tert-butylperoxy benzoate, tert-amylperoxy benzoate, 1,1,3,3-tetramethyl
butyl-1-peroxy benzoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy benzoate, tert-butylperoxy
3,3,5-trimethylhexanoate, tert-amylperoxy 3,3,5-trimethylhexanoate, 1,1,3,3-tetramethyl
butyl-1-peroxy 3,3,5-trimethylhexanoate, 1,1-dimethyl-3-hydroxy butyl-1-peroxy 3,3,5-trimethylhexanoate,
tert-butylperoxy isobutyrate, tert-amylperoxy isobutyrate, 1,1,3,3-tetramethyl butyl-1-peroxy
isobutyrate, and 1,1-dimethyl-3-hydroxy butyl-1-peroxy isobutyrate, dialkylperoxides,
preferably di-tert-butyl peroxide, tert-butyl tert-amyl peroxide, and di-tert-amyl
peroxide, and diacylperoxides, preferably bis(3,3,5-trimethylhexanoyl) peroxide.
1. Ein Verfahren zur Herstellung eines Polymers mithilfe eines radikalischen Polymerisationsverfahrens,
wobei mindestens 25 % (Gew./Gew.) des Phlegmatisierers, der verwendet wurde zum Phlegmatisieren
des Peroxids oder der Peroxide, die als eine Quelle von freien Radikalen im Verfahren
verwendet wurden, so reagiert wird, dass er nicht aus dem Polymer extrahierbar ist,
durch Transportieren eines Behälters, welcher eine Peroxidformulierung enthält, zur
Polymerisationseinheit und Einführen seines Inhaltes in das Polymerisationsverfahren,
wobei der Behälter ein Fassungsvermögen größer als 1 Liter aufweist und befüllt wird
mit:
• 90 bis 1 % (Gew./Gew.) eines oder mehrerer Peroxide, ausgewählt aus der Gruppe bestehend
aus Peroxyestern, einschließlich Peroxyesterderivaten von Ketonperoxiden, Peroxycarbonaten,
einschließlich Peroxycarbonatderivaten von Ketonperoxiden, Diacylperoxiden mit 1 bis
48 Kohlenstoffatomen, Diperoxyketalen, Trioxepanen, Dialkylperoxiden, gemischten Peroxiden,
die zwei verschiedene Peroxid tragende Einheiten in einem Molekül enthalten, und Gemischen
aus zwei oder mehreren dieser Peroxide,
• 10 bis 99 % (Gew./Gew.) eines oder mehrerer Phlegmatisierer mit einem (gemeinsamen)
Flammpunkt über 5° C und einem (gemeinsamen) Siedepunkt, der mehr als 60° C über der
selbstbeschleunigenden Zersetzungstemperatur der Peroxidformulierung liegt, wobei
der Phlegmatisierer aus der Gruppe bestehend aus 1-Hexen, 1-Hepten, 1-Octen, 1-Nonen,
1-Decen, 1-Undecen, 1-Dodecen und Gemischen davon ausgewählt ist,
• 0 - 75 % (Gew./Gew.) an gegebenenfalls konventionellen Phlegmatisierern, ausgewählt
aus Kohlenwasserstoffen und oxygenierten Kohlenwasserstoffen,
bis zu einer Gesamtmenge von 100 %.
2. Das Verfahren nach Anspruch 1, wobei es sich bei dem Polymerisationsverfahren um ein
Hochdruck-Ethylen-(Co)polymerisationsverfahren handelt.
3. Das Verfahren nach Anspruch 1, wobei es sich bei dem Polymerisationsverfahren um ein
Suspensions-(Co)polymerisationsverfahren von Styrol handelt.
4. Ein Verfahren nach einem der vorhergehenden Ansprüche, wobei das Peroxid ausgewählt
ist aus der Gruppe bestehend aus 1,1,4,4-Tetramethylbutyl-1,4-di(peroxy-2-methylpropanoat),
tert-Butylperoxy-neodecanoat, tert-Amylperoxy-neodecanoat, 1,1,3,3-Tetramethylbutyl-1-peroxy-neodecanoat,
1,1-Dimethyl-3-hydroxy-butyl-1-peroxyneodecanoat, tert-Butylperoxy-pivalat, tert-Amylperoxy-pivalat,
1,1,3,3-Tetramethyl-butyl-1-peroxy-pivalat, 1,1-Dimethyl-3 -hydroxy-butyl-1-peroxy-pivalat,
tert-Butylperoxy-2-ethylhexanoat, tert-Amylperoxy-2-ethylhexanoat, 1,1,3,3-Tetramethyl-butyl-1-peroxy-2-ethylhexanoat,
1, 1-Dimethyl-3-hydroxy-butyl-1-peroxy-2-ethylhexanoat, tert-Butylperoxy-benzoat,
tert-Amylperoxy-benzoat, 1,1,3,3-Tetramethylbutyl-1-peroxy-benzoat, 1,1-Dimethyl-3-hydroxy-butyl-1-peroxy-benzoat,
tert-Butylperoxy-3,3,5-trimethylhexanoat, tert-Amylperoxy-3,3,5-trimethylhexanoat,
1,1,3,3-Tetramethyl-butyl-1-peroxy-3,3,5-trimethylhexanoat, 1,1-Dimethyl-3-hydroxy-butyl-1-peroxy-3,3,5-trimethylhexanoat,
tert-Butylperoxy-isobutyrat, tert-Amylperoxyisobutyrat, 1,1,3,3-Tetramethyl-butyl-1-peroxy-isobutyrat
und 1,1-Dimethyl-3-hydroxy-butyl-1-peroxy-isobutyrat, Dialkylperoxiden, vorzugsweise
Di-tert-butyl-peroxid, tert-Butyl-tert-amyl-peroxid und Di-tert-amyl-peroxid, und
Diacylperoxiden, vorzugsweise Bis(3,3,5-trimethylhexanoyl)-peroxid.
1. Procédé de fabrication d'un polymère au moyen d'un processus de polymérisation radicalaire
dans lequel au moins 25 % m/m du phlegmatisant qui a été utilisé pour phlegmatiser
le peroxyde ou les peroxydes utilisé(s) comme source de radicaux libres dans ledit
processus est mis en réaction de sorte qu'il ne soit pas extractible du polymère lors
du transport d'un récipient contenant une formulation de peroxyde vers l'unité de
polymérisation et de l'introduction de son contenu dans le processus de polymérisation,
ledit récipient ayant une taille supérieure à 1 litre et étant rempli avec :
- 90 à 1 % m/m d'un ou plusieurs peroxydes choisis dans le groupe constitué de peresters,
comprenant des dérivés de perester de peroxydes de cétone, de peroxycarbonates, y
compris de dérivés de peroxycarbonate de peroxydes de cétone, de diacylperoxydes ayant
de 1 à 48 atomes de carbone, de diperoxycétals, trioxépanes, diakylperoxydes, peroxydes
mixtes contenant deux groupes caractéristiques différents contenant du peroxygène
dans une molécule, et des mélanges de n'importe quels de deux ou plus de ces peroxydes,
- 10 à 99 % m/m d'un ou plusieurs phlegmatisants avec un point d'éclair (commun) supérieur
à 5°C et un point d'ébullition (commun) qui est supérieur de 60°C à la température
de décomposition auto-accélérée de la formulation de peroxyde, ledit phlegmatisant
étant choisi dans le groupe constitué de 1-hexène, 1-heptène, 1-octène, 1-nonène,
1-décène, 1-undécène, 1-dodécène et de mélanges de ceux-ci,
- 0 à 75 % m/m de phlegmatisants classiques éventuels choisis parmi des hydrocarbures
et des hydrocarbures oxygénés,
jusqu'à un total de 100 %.
2. Procédé selon la revendication 1, dans lequel le processus de polymérisation est un
processus de (co)polymérisation d'éthylène à haute pression.
3. Procédé selon la revendication 1 , dans lequel le processus de polymérisation est
un processus de (co)polymérisation de styrène en suspension.
4. Procédé selon l'une quelconque des revendications précédentes dans lequel le peroxyde
est choisi dans le groupe constitué de 1,1,4,4-tétraméthylbutyl-1,4-di(peroxy-2-méthylpropanoate),
tert-butylperoxy-néodécanoate, tert-amylperoxy-néodécanoate, 1,1,3,3-tétraméthylbutyl-1-peroxy-néodécanoate,
1 , 1-diméthyl-3-hydroxybutyl-1-peroxy-néodécanoate, tert-butylperoxy-pivalate, tert-amylperoxy-pivalate,
1,1,3,3-tétraméthylbutyl-1-peroxy-pivalate, 1 , 1-diméthyl-3-hydroxybutyl-1-peroxy-pivalate,
tert-butylperoxy-2-éthylhexanoate, tert-amylperoxy-2-éthylhexanoate, 1,1,3,3-tétraméthylbutyl-1-peroxy-2-éthylhexanoate,
1,1-diméthyl-3-hydroxybutyl-1-peroxy-2-éthylhexanoate, tert-butylperoxy-benzoate,
tert-amylperoxy-benzoate, 1,1,3,3-tétraméthylbutyl-1-peroxy-benzoate, 1,1-d iméthyl-3-hydroxybutyl-1-peroxy
benzoate, tert-butylperoxy-3,3,5-triméthylhexanoate, tert-amylperoxy-3,3,5-triméthylhexanoate,
1,1,3,3-tétraméthylbutyl-1-peroxy-3,5-triméthylhexanoate, 1 , 1-diméthyl-3-hydroxybutyl-1-peroxy-3,3,5-triméthylhexanoate,
tert-butylperoxy-isobutyrate, tert-amylperoxy- isobutyrate, 1,1,3,3-tétraméthylbutyl-1-peroxy-isobutyrate
et 1,1-diméthyl-3-hydroxybutyl-1-peroxy-isobutyrate, dialkylperoxydes, de préférence
peroxyde de di-tert-butyle, peroxyde de tert-butyle tert-amyle et peroxyde de di-tert-amyle
et diacylperoxydes, de préférence bis(3,3,5-triméthylhexanoyl)peroxyde.